

26/02/03
2603607994

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 March 2002 (07.03.2002)

PCT

(10) International Publication Number
WO 02/18333 A1

(51) International Patent Classification⁷: **C07C 323/20**,
C07D 333/54, 327/06, 307/87, 333/72, C07C 311/37,
C07D 215/18, 239/74, 277/62, A61K 31/18, 31/38, 31/39,
31/34, 31/135, 31/47

(21) International Application Number: PCT/IB01/01521

(22) International Filing Date: 22 August 2001 (22.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0021593.9 31 August 2000 (31.08.2000) GB
0107116.6 21 March 2001 (21.03.2001) GB

(71) Applicant (for GB only): **PFIZER LIMITED** [GB/GB];
Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(71) Applicant (for all designated States except GB, US):
PFIZER INC. [US/US]; 235 East 42nd Street, New York,
NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ADAM, Mavis, Diane** [US/US]; Pfizer Global Research and Development,
Eastern Point Road, Groton, CT 06340 (US). **ANDREWS, Mark, David** [GB/GB]; Pfizer Global Research and Development,
Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **ELLIOTT, Mark, Leonard** [US/US]; Pfizer
Global Research and Development, Eastern Point Road,
Groton, CT 06340 (US). **GYMER, Geoffrey, Edward**
[GB/GB]; Pfizer Global Research and Development,
Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **HEP-
WORTH, David** [GB/GB]; Pfizer Global Research and

Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **HOWARD, Harry, Ralph, Jr.** [US/US];
Pfizer Global Research and Development, Eastern Point
Road, Groton, CT 06340 (US). **MIDDLETON, Donald, Stuart** [GB/GB]; Pfizer Global Research and Develop-
ment, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).
STOBIE, Alan [GB/GB]; Pfizer Global Research and
Development, Ramsgate Road, Sandwich, Kent CT13 9NJ
(GB).

(74) Agents: **WOOD, David, J.** et al.; Pfizer Limited, Rams-
gate Road, Sandwich, Kent CT13 9NJ (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PHENOXYBENZYLAMINE DERIVATIVES AS SELECTIVE SEROTONIN RE-UP TAKE INHIBITORS

(57) Abstract: A compound of general formula (I) wherein R¹ and R² are H, C₁-C₆alkyl or (CH₂)_d(C₃-C₆cycloalkyl) wherein d = 0, 1, 2 or 3; or R¹ and R² together with the nitrogen to which they are attached from an azetidine ring; Z or Y is -SR³ and the other Z or Y is halogen or -R³; wherein R³ is C₁-C₄ alkyl optionally substituted with fluorine; except that R³ is not CF₃; or Z and Y are linked so that, together with the interconnecting atoms, Z and Y form a fused 5 to 7-membered carbocyclic or heterocyclic ring, and wherein when Z and Y form a heterocyclic ring, in addition to carbon atoms, the linkage contains one or two heteroatoms independently selected from oxygen, sulfur and nitrogen; R⁴ and R⁵, which may be the same or different, are: A-X, wherein A = -CH=CH- or -(CH₂)_p- where p is 0, 1 or 2; X is hydrogen, F, Cl, Br, I, CONR⁶R⁷, SO₂NR⁶R⁷, SO₂NHC(=O)R⁶, OH, C₁₋₄alkoxy, NR⁸SO₂R⁹, NO₂, NR⁹R¹¹, CN, CO₂R¹⁰, CHO, SR¹⁰, S(O)R⁹ or SO₂R¹⁰; or a 5- or 6-membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, S and O, optionally substituted independently by one or more R¹³; wherein R¹³ is hydroxy, C₁-C₄alkoxy, F, C₁-C₆alkyl, haloalkyl, haloalkoxy, -NH₂, NII(C₁-C₆alkyl) or -N(C₁-C₆alkyl)₂. The compounds of general formula (I) inhibit monoamine reuptake and in particular exhibit activity as selective serotonin reuptake inhibitors.

WO 02/18333 A1



162162



ACTION